Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Commit Biologics
Deal Size : $17.2 million
Deal Type : Financing
Commit Biologics Launches with €16M Seed Financing for Cancer and Autoimmune Disease
Details : Commit is advancing its BiCE™ platform using single domain antibodies to activate the complement system for cancer and autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Commit Biologics
Deal Size : $17.2 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Metrion Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, Bioqube and Metrion will advance a lead series of previously identified highly potent and selective small molecule inhibitors of the human Kv1.3 potassium ion channel to enable further development.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Metrion Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration